other material
confidence high
sentiment positive
materiality 0.80
Immunovant announces positive initial Phase 1 data for IMVT-1402 with IgG reductions and no albumin or LDL-C changes
Immunovant, Inc.
- Mean total IgG reduction of 63% after four weekly 300 mg SC doses of IMVT-1402 in Phase 1 MAD cohort.
- No decrease in serum albumin below baseline or increase in LDL-C above baseline observed after 4 weeks.
- Subcutaneous doses of IMVT-1402 achieved peak IgG reductions similar to those previously seen with batoclimab.
- All adverse events were mild or moderate; dosing for 600 mg cohort has recently begun.
- Immunovant hosted a conference call and webcast on September 26, 2023 to discuss the data.